Magazines and books

Publications and Presentations

Published data and presentations from medical conferences for Karyopharm’s investigational drug candidates

This page is intended to provide scientific information to scientific research professionals. XPOVIO (selinexor) has only been approved by the United States Food and Drug Administration (FDA) for the following indications:

• In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.


For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.


In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Karyopharm’s other drug candidates, including selinexor in additional indications, are investigational medicines and have not been approved by FDA, Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.  

Featured Research

Multiple Myeloma

Posters and Presentations

  1. Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Patients with Multiple Myeloma (MM) After 1-3 Prior Therapies: Initial Results of the Phase 3 BOSTON Study
  2. Selinexor, Daratumumab, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM)
  3. Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd) For Patients with Relapsed/Refractory Multiple Myeloma
  4. Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
  5. Selinexor, Lenalidomide, and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma
  6. Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
  7. Results of the Pivotal STORM Study (Part 2): Deep and Durable Responses with Oral Selinexor plus Low Dose Dexamethasone in Patients with Penta-Exposed and Triple Class Refractory MM
  8. Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated With Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies
  9. Selinexor Combined with Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate in Patients with Relapsed or Refractory Multiple Myeloma (MM)
  10. Improved Overall Survival (OS) with Oral Selinexor Plus Low Dose Dexamethasone (Sd) in Patients with Triple Class Refractory Multiple Myeloma (TCR-MM) Compared to FLATIRON – Real World Evidence
  11. Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selienxor, Bortezomib, and Dexamethasone in Comparison with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis From the BOSTON Study
  12. Once Weekly Selinexor, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses From the Phase 3 BOSTON Study
  13. Impact of Prior Therapies on the Safety and Efficacy of Once-Weekly Selinexor, Bortezomib, and Dexamethasone Compared With Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the BOSTON Study
  14. Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 BOSTON Study

Diffuse Large B-cell Lymphoma (DLBCL)


Other Hematologic Malignancies


Solid Tumors



COVID-19

  1. Treatment of Severe COVID-19 with Low-Dose Selinexor: Demonstration of Anti-Viral and Anti-Inflammatory Activities in a Randomized, International, Multicenter, Placebo-Controlled Phase 2 Clinical Trial